1990-2021年全球细菌抗微生物药物耐药性负担:一项系统分析及至2050年的预测
该研究估算了1990至2021年204个国家和地区22种病原体、84种病原体-药物组合及11种感染综合征的细菌抗微生物药物耐药性(AMR)归因和相关性死亡与伤残调整生命年(DALYs),并预测至2050年。
要点
- 1990至2021年,5岁以下儿童AMR死亡下降超过50%,70岁及以上成人上升超过80%。
核心结论
- 该研究首次全面评估1990至2021年全球AMR负担并预测至2050年。
- 5岁以下儿童AMR死亡下降提示感染预防的重要性,70岁以上人群AMR负担呈令人担忧的上升趋势。
- 作者认为干预措施应结合感染预防、疫苗接种、减少农业和人类中不适当抗生素使用以及新抗生素研究,以减轻2050年预测的AMR死亡数。
研究设计与样本
- 系统分析,纳入1990至2021年204个国家和地区、22种病原体、84种病原体-药物组合及11种感染综合征。
- 采用统计建模估算所有地点的AMR负担,包括无数据地点;基于五个组分量的估计:涉及脓毒症的死亡数、归因于特定感染综合征的感染死亡比例、归因于特定病原体的感染综合征死亡比例、特定病原体对目标抗生素耐药百分比、以及耐药相关的超额死亡风险或感染持续时间。
- AMR归因和相关负担基于两种反事实定义:所有耐药感染被药物敏感感染替代的情景,以及所有耐药感染被无感染替代的情景。
- 产生至2050年的全球和区域预测,包括三种情景:参考情景(最可能未来的概率预测)、革兰阴性药物情景(假设未来针对革兰阴性病原体的药物开发)和更好护理情景(假设未来医疗质量和适当抗微生物药物可及性改善)。
主要发现
- 1990至2021年,5岁以下儿童AMR死亡下降超过50%,70岁及以上成人上升超过80%;5岁以下儿童AMR死亡率在所有超级区域均下降,而5岁及以上人群AMR死亡率在所有超级区域均上升。
- 对于AMR相关死亡和归因死亡,耐甲氧西林金黄色葡萄球菌全球增幅最大:相关死亡从1990年261 000(95% UI 150 000-372 000)增至2021年550 000(500 000-600 000),归因死亡从1990年57 200(34 100-80 300)增至2021年130 000(113 000-146 000)。
临床怎么用
- 作者认为感染预防重要,5岁以下儿童AMR死亡下降支持这一点。
- 作者认为鉴于AMR负担随地点和年龄高度变异,干预措施应结合感染预防、疫苗接种、减少农业和人类中不适当抗生素使用以及新抗生素研究,以减轻2050年预测的AMR死亡数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antimicrobial resistance (AMR) poses an important global health challenge in the 21st century. A previous study has quantified the global and regional burden of AMR for 2019, followed with additional publications that provided more detailed estimates for several WHO regions by country. To date, there have been no studies that produce comprehensive estimates of AMR burden across locations that encompass historical trends and future forecasts. METHODS: We estimated all-age and age-specific deaths and disability-adjusted life-years (DALYs) attributable to and associated with bacterial AMR for 22 pathogens, 84 pathogen-drug combinations, and 11 infectious syndromes in 204 countries and territories from 1990 to 2021. We collected and used multiple cause of death data, hospital discharge data, microbiology data, literature studies, single drug resistance profiles, pharmaceutical sales, antibiotic use surveys, mortality surveillance, linkage data, outpatient and inpatient insurance claims data, and previously published data, covering 520 million individual records or isolates and 19 513 study-location-years. We used statistical modelling to produce estimates of AMR burden for all locations, including those with no data. Our approach leverages the estimation of five broad component quantities: the number of deaths involving sepsis; the proportion of infectious deaths attributable to a given infectious syndrome; the proportion of infectious syndrome deaths attributable to a given pathogen; the percentage of a given pathogen resistant to an antibiotic of interest; and the excess risk of death or duration of an infection associated with this resistance. Using these components, we estimated disease burden attributable to and associated with AMR, which we define based on two counterfactuals; respectively, an alternative scenario in which all drug-resistant infections are replaced by drug-susceptible infections, and an alternative scenario in which all drug-resistant infections were replaced by no infection. Additionally, we produced global and regional forecasts of AMR burden until 2050 for three scenarios: a reference scenario that is a probabilistic forecast of the most likely future; a Gram-negative drug scenario that assumes future drug development that targets Gram-negative pathogens; and a better care scenario that assumes future improvements in health-care quality and access to appropriate antimicrobials. We present final estimates aggregated to the global, super-regional, and regional level. FINDINGS: In 2021, we estimated 4·71 million (95% UI 4·23-5·19) deaths were associated with bacterial AMR, including 1·14 million (1·00-1·28) deaths attributable to bacterial AMR. Trends in AMR mortality over the past 31 years varied substantially by age and location. From 1990 to 2021, deaths from AMR decreased by more than 50% among children younger than 5 years yet increased by over 80% for adults 70 years and older. AMR mortality decreased for children younger than 5 years in all super-regions, whereas AMR mortality in people 5 years and older increased in all super-regions. For both deaths associated with and deaths attributable to AMR, meticillin-resistant Staphylococcus aureus increased the most globally (from 261 000 associated deaths [95% UI 150 000-372 000] and 57 200 attributable deaths [34 100-80 300] in 1990, to 550 000 associated deaths [500 000-600 000] and 130 000 attributable deaths [113 000-146 000] in 2021). Among Gram-negative bacteria, resistance to carbapenems increased more than any other antibiotic class, rising from 619 000 associated deaths (405 000-834 000) in 1990, to 1·03 million associated deaths (909 000-1·16 million) in 2021, and from 127 000 attributable deaths (82 100-171 000) in 1990, to 216 000 (168 000-264 000) attributable deaths in 2021. There was a notable decrease in non-COVID-related infectious disease in 2020 and 2021. Our forecasts show that an estimated 1·91 million (1·56-2·26) deaths attributable to AMR and 8·22 million (6·85-9·65) deaths associated with AMR could occur globally in 2050. Super-regions with the highest all-age AMR mortality rate in 2050 are forecasted to be south Asia and Latin America and the Caribbean. Increases in deaths attributable to AMR will be largest among those 70 years and older (65·9% [61·2-69·8] of all-age deaths attributable to AMR in 2050). In stark contrast to the strong increase in number of deaths due to AMR of 69·6% (51·5-89·2) from 2022 to 2050, the number of DALYs showed a much smaller increase of 9·4% (-6·9 to 29·0) to 46·5 million (37·7 to 57·3) in 2050. Under the better care scenario, across all age groups, 92·0 million deaths (82·8-102·0) could be cumulatively averted between 2025 and 2050, through better care of severe infections and improved access to antibiotics, and under the Gram-negative drug scenario, 11·1 million AMR deaths (9·08-13·2) could be averted through the development of a Gram-negative drug pipeline to prevent AMR deaths. INTERPRETATION: This study presents the first comprehensive assessment of the global burden of AMR from 1990 to 2021, with results forecasted until 2050. Evaluating changing trends in AMR mortality across time and location is necessary to understand how this important global health threat is developing and prepares us to make informed decisions regarding interventions. Our findings show the importance of infection prevention, as shown by the reduction of AMR deaths in those younger than 5 years. Simultaneously, our results underscore the concerning trend of AMR burden among those older than 70 years, alongside a rapidly ageing global community. The opposing trends in the burden of AMR deaths between younger and older individuals explains the moderate future increase in global number of DALYs versus number of deaths. Given the high variability of AMR burden by location and age, it is important that interventions combine infection prevention, vaccination, minimisation of inappropriate antibiotic use in farming and humans, and research into new antibiotics to mitigate the number of AMR deaths that are forecasted for 2050. FUNDING: UK Department of Health and Social Care's Fleming Fund using UK aid, and the Wellcome Trust.
引用
- Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. Lancet. 2024. PMID: 39299261. doi:10.1016/S0140-6736(24)01867-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。